ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$59.66 USD
-0.72 (-1.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $59.68 +0.02 (0.03%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
ANIP 59.66 -0.72(-1.19%)
Will ANIP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANIP
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Other News for ANIP
ANI Pharmaceuticals price target raised by $2 at Raymond James, here's why
ANI Pharmaceuticals Inc (ANIP) Trading 6.85% Higher on Sep 17
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
ANI Pharmaceuticals’ Acquisition of Alimera Sciences Bolsters Buy Rating and $94 Target Price
ANI Pharmaceuticals Inc (ANIP) Shares Gap Down to $56.61 on Sep 16